LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded
NEWS 28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 29	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 30	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 APR 2007  HIGHEST RN 929721-97-1
DICTIONARY FILE UPDATES:  11 APR 2007  HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> E "CAPTOPRIL"/CN 25
E1            1     CAPTOPRDS/CN
E2            1     CAPTOPRESS/CN
E3            1 --> CAPTOPRIL/CN
E4            1     CAPTOPRIL DISULFIDE/CN
E5            1     CAPTOPRIL GLUTATHIONE DISULFIDE/CN
E6            1     CAPTOPRIL HYDROCHLORIDE/CN
E7            1     CAPTOPRIL METHYLTRANSFERASE/CN
E8            1     CAPTOPRIL THIOL METHYLTRANSFERASE/CN
E9            1     CAPTOPRIL TZ/CN
E10           1     CAPTOPRIL-FRUSEMIDE MIXT./CN
E11           1     CAPTOPRIL-HYDROCHLOROTHIAZIDE MIXT./CN
E12           1     CAPTOPRIL-KETANSERIN MIXT./CN
E13           1     CAPTOPRIL-THIAZIDE/CN
E14           1     CAPTOR/CN
E15           1     CAPTORIL/CN
E16           1     CAPTOSTIBONE/CN
E17           1     CAPTROL/CN
E18           2     CAPTURE/CN
E19           1     CAPTURE (PESTICIDE)/CN
E20           1     CAPTURE (POLYMER)/CN
E21           1     CAPTURE SPIRAL SILK PROTEIN (NEPHILA CLAVIPES FLAGELLIFORM GLAND
C-TERMINAL FRAGMENT)/CN
E22           1     CAPTURE SPIRAL SILK PROTEIN (NEPHILA CLAVIPES FLAGELLIFORM GLAND
PRECURSOR N-TERMINAL FRAGMENT)/CN
E23           1     CAPTURE WR 6/CN
E24           1     CAPTURE-DIMETHOATE MIXT./CN
E25           1     CAPTURE-ORTHENE MIXT./CN

=> S E3
L1            1 CAPTOPRIL/CN

=> E "LOSARTAN"/CN 25
```

```
E1            1      LOSAN/CN
E2            1      LOSANTIN/CN
E3            1 --> LOSARTAN/CN
E4            1      LOSARTAN MONOPOTASSIUM SALT/CN
E5            1      LOSARTAN P-TOLUENESULFONATE/CN
E6            1      LOSARTAN POTASSIUM/CN
E7            1      LOSARTAN POTASSIUM SALT/CN
E8            1      LOSARTAN-HYDROCHLOROTHIAZIDE MIXT./CN
E9            1      LOSBANINE/CN
E10           1      LOSE-URONATE KETOL-ISOMERASE (YERSINIA PESTIS STRAIN CO92 GENE
KDUI)/CN
E11           1      LOSEC/CN
E12           1      LOSEC SODIUM/CN
E13           1      LOSEYITE/CN
E14           1      LOSFERRON/CN
E15           1      LOSIGAMONE/CN
E16           1      LOSIL 1000-50/CN
E17           1      LOSIL 1000-65/CN
E18           1      LOSIL 800-50/CN
E19           1      LOSIL 800-65/CN
E20           1      LOSINDOLE/CN
E21           1      LOSIUM/CN
E22           1      LOSK/CN
E23           1      LOSMIPROFEN/CN
E24           1      LOSO PREP/CN
E25           1      LOSOL BLUE/CN

=> S E3
L2            1 LOSARTAN/CN

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                10.35      10.56

FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Apr 2007  VOL 146 ISS 16
FILE LAST UPDATED: 11 Apr 2007  (20070411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1/thu
          5249 L1
        877695 THU/RL
L3        2324 L1/THU
                (L1 (L) THU/RL)
```

```
=> s l2/thu
          2711 L2
        877695 THU/RL
L4        1975 L2/THU
                 (L2 (L) THU/RL)

=> s cancer? or neoplas? or tumor? or carcinom?
        327650 CANCER?
        488538 NEOPLAS?
        465070 TUMOR?
        166706 CARCINOM?
L5      788148 CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?

=> s l3 (L) l5
L6           26 L3 (L) L5

=> s l6 not py>2000
       7043137 PY>2000
L7             8 L6 NOT PY>2000

=> s l7 and human
       1758388 HUMAN
        345672 HUMANS
       1926622 HUMAN
                 (HUMAN OR HUMANS)
L8             4 L7 AND HUMAN

=> d ibib 1-4

L8   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1999:794097  CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER:          132:18639
TITLE:                    Do ACE-inhibitors suppress tumor necrosis
                          factor-α production in advanced chronic renal
                          failure?
AUTHOR(S):                Stenvinkel, P.; Andersson, P.; Wang, T.; Lindholm, B.;
                          Bergstrom, J.; Palmblad, J.; Heimburger, O.;
                          Cederholm, T.
CORPORATE SOURCE:         Departments of Clinical Science, Divisions of Renal
                          Medicine and Baxter Novum, Stockholm, Swed.
SOURCE:                   Journal of Internal Medicine (1999), 246(5), 503-507
                          CODEN: JINMEO; ISSN: 0954-6820
PUBLISHER:                Blackwell Science Ltd.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          22    THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1999:473537  CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER:          132:44577
TITLE:                    Influence of putative antiinvasive agents on matrix
                          metalloproteinase secretion by human
                          neoplastic glia in vitro
AUTHOR(S):                Rooprai, H. K.; Kandanearatachi, A.; Rucklidge, G.;
                          Pilkington, G. J.
CORPORATE SOURCE:         Department of Neuropathology, Institute of Psychiatry,
                          London, SE5 8AF, UK
SOURCE:                   Annals of the New York Academy of Sciences (1999),
                          878(Inhibition of Matrix Metalloproteinases), 654-657
                          CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER:                New York Academy of Sciences
DOCUMENT TYPE:            Journal
```

```
LANGUAGE:                English
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 3 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        1998:238843  CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER:         128:317013
TITLE:                   Captopril inhibits tumor growth in a xenograft model
                         of human renal cell carcinoma
AUTHOR(S):               Hii, S. -I.; Nicol, D. L.; Gotley, D. C.; Thompson, L.
                         C.; Green, M. K.; Jonsson, J. R.
CORPORATE SOURCE:        Department of Surgery, Princess Alexandra Hospital,
                         University of Queensland, Woolloongabba, 4102,
                         Australia
SOURCE:                  British Journal of Cancer (1998), 77(6), 880-883
                         CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER:               Churchill Livingstone
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         25    THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        1997:561786  CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER:         127:229321
TITLE:                   Captopril modulates hormone receptor concentration and
                         inhibits proliferation of human mammary
                         ductal carcinoma cells in culture
AUTHOR(S):               Small, William, Jr.; Molteni, Agostino; Kim, Yoon T.;
                         Taylor, Joann M.; Chen, Zehan; Ward, William F.
CORPORATE SOURCE:        Department of Radiology, Northwestern University
                         Medical School, Chicago, IL, USA
SOURCE:                  Breast Cancer Research and Treatment (1997), 44(3),
                         217-224
                         CODEN: BCTRD6; ISSN: 0167-6806
PUBLISHER:               Kluwer
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         21    THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007)

     FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007
               E "CAPTOPRIL"/CN 25
L1             1 S E3
               E "LOSARTAN"/CN 25
L2             1 S E3

     FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007
L3          2324 S L1/THU
L4          1975 S L2/THU
L5        788148 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L6            26 S L3 (L) L5
L7             8 S L6 NOT PY>2000
L8             4 S L7 AND HUMAN

=> s l4 (L) l5
L9            10 L4 (L) L5

=> d ibib 1-9
```

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:182557 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:267234
TITLE: Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells
AUTHOR(S): Liu, Wen-Bin; Wang, Xing-Peng; Wu, Kai; Zhang, Ru-Ling
CORPORATE SOURCE: Shanghai No. 1 People's Hospital, Shanghai Jiaotong University, Shanghai, 200080, Peop. Rep. China
SOURCE: World Journal of Gastroenterology (2005), 11(41), 6489-6494
CODEN: WJGAF2; ISSN: 1007-9327
PUBLISHER: World Journal of Gastroenterology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:101964 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:184652
TITLE: Novel pathways in the etiology of cancer, and treatment methods
INVENTOR(S): Benz, Christopher C.
PATENT ASSIGNEE(S): Buck Institute for Age Research, USA
SOURCE: U.S. Pat. Appl. Publ., 49 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006024691	A1	20060202	US 2005-90546		20050324
PRIORITY APPLN. INFO.:			US 2004-556774P	P	20040325
			US 2004-580534P	P	20040616
			US 2004-629691P	P	20041119

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1284893 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:285876
TITLE: TGF-β and TNF-α producing effects of losartan and amlodipine on human mononuclear cell culture
AUTHOR(S): Kaynar, Kubra; Ulusoy, Sukru; Ovali, Ercument; Vanizor, Birgul; Dikmen, Tamer; Gul, Semih
CORPORATE SOURCE: Department of Nephrology, School of Medicine, Karadeniz Technical University, Trabzon, Turk.
SOURCE: Nephrology (2005), 10(5), 478-482
CODEN: NEPHF2; ISSN: 1320-5358
PUBLISHER: Blackwell Publishing Asia Pty Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1213085 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:225211
TITLE: G protein-coupled receptors as targets for drug discovery
AUTHOR(S): Esbenshade, Timothy A.

CORPORATE SOURCE: Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
SOURCE: Drug Discovery Series (2006), Volume 4, Issue G Protein-Coupled Receptors in Drug Discovery, 15-36. CRC Press LLC: Boca Raton, Fla.
CODEN: DDSRBS
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1188658 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:16589
TITLE: Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells
AUTHOR(S): Uemura, Hiroji; Ishiguro, Hitoshi; Nagashima, Yoji; Sasaki, Takeshi; Nakaigawa, Noboru; Hasumi, Hisashi; Kato, Shingo; Kubota, Yoshinobu
CORPORATE SOURCE: Department of Urology and Second Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
SOURCE: Molecular Cancer Therapeutics (2005), 4(11), 1699-1709
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:291659 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 143:323408
TITLE: Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
AUTHOR(S): Arrieta, O.; Guevara, P.; Escobar, E.; Garcia-Navarrete, R.; Pineda, B.; Sotelo, J.
CORPORATE SOURCE: Neuroimmunology Unit of the National Institute of Neurology and Neurosurgery of Mexico, Mexico City, 14269, Mex.
SOURCE: British Journal of Cancer (2005), 92(7), 1247-1252
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:862779 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 139:345909
TITLE: Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
INVENTOR(S): Suthanthiran, Manikkam; Maluccio, Mary
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6641811	B1	20031104	US 2001-781146		20010209
US 2004067233	A1	20040408	US 2003-627408		20030725
PRIORITY APPLN. INFO.:			US 2000-181485P	P	20000210
			US 2001-781146	A3	20010209

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:849376 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 137:358120
TITLE: Compositions and methods for treating colorectal polyps and cancer
INVENTOR(S): Tamura, Masaaki
PATENT ASSIGNEE(S): Vanderbilt University, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002087503	A2	20021107	WO 2002-US13383		20020426
WO 2002087503	A3	20031009			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002311859	A1	20021111	AU 2002-311859		20020426
US 2003083339	A1	20030501	US 2002-133056		20020426
PRIORITY APPLN. INFO.:			US 2001-286621P	P	20010426
			WO 2002-US13383	W	20020426

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:209554 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 135:298256
TITLE: Angiotensin II receptor blockade: a novel strategy to prevent immunosuppressant-associated cancer progression
AUTHOR(S): Maluccio, M.; Sharma, V.; Lagman, M.; Konijn, G.; Suthanthiran, M.
CORPORATE SOURCE: Department of Transplantation and Extracorporeal Therapy, Division of Nephrology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
SOURCE: Transplantation Proceedings (2001), 33(1-2), 1820-1821
CODEN: TRPPA8; ISSN: 0041-1345
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file pctfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        33.30     43.86

FILE 'PCTFULL' ENTERED AT 12:54:54 ON 12 APR 2007
COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED:         10 APR 2007      <20070410/UP>
MOST RECENT UPDATE WEEK:       200714        <200714/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s captopril
          3750 CAPTOPRIL
             7 CAPTOPRILS
L10       3752 CAPTOPRIL
                (CAPTOPRIL OR CAPTOPRILS)

=> s losartan
          1805 LOSARTAN
             1 LOSARTANS
L11       1805 LOSARTAN
                (LOSARTAN OR LOSARTANS)

=> s l10 or l11
L12       4267 L10 OR L11

=> s cancer? or neoplas? or tumor? or carcinom?
         87176 CANCER?
         25305 NEOPLAS?
         72460 TUMOR?
         34117 CARCINOM?
L13     110137 CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?

=> s l13 and l12
L14       2500 L13 AND L12

=> s l14 not py>1999
        807628 PY>1999
L15        311 L14 NOT PY>1999

=> d ibib kwic

L15    ANSWER 1 OF 311   PCTFULL   COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER:       2001062725 PCTFULL
       no bibliographic data available - please use FPI for PI information
DESIGNATED STATES

DETD   Both the growth and metastasis of solid tumors are also
       angiogenesis-
       dependent (Folkman, 1986, J. Cancer Res. 46:467-473; Folkman,
       1989, J. Nat. Cancer
       Inst. 82:4-6; Follmian et al. 1995, Tumor Angiogenesis,
       Chapter 10, pp. 206-32, in
       The Molecular Basis of Cancer, Mendelsohn et al., eds. (W. B.
       Saunders). It has been
       shown for example, that tumors which enlarge to greater than
       about 2 mm in diameter
       must obtain their own blood supply and do so by inducing the growth of
       new capillary
       blood vessels. After these new blood vessels become embedded in the
       tumor, they
```

provide nutrients and growth factors essential for tumor growth as well as a means for I 0 tumor cells to enter the circulation and metastasize to distant sites, such as liver, lung or bone (W'cidnerl991, New Eng. J. Med. 324(l):1-8). When used as drugs in tumor-bearing animals, natural inhibitors of angiogenesis can prevent the growth of small tumors (O'Reilly et al., 1994, Cell 79:315-328). Indeed, in some protocols, the application of such inhibitors leads to tumor regression and dormancy even after cessation of treatment (O'Reilly et al., 1997, Cell 88:277-285). Moreover, supplying inhibitors of angiogenesis to certain tumors can potentiate their response to other therapeutic regimens (e.g., chemotherapy) (see, e.g., Teischer et al., 1994, Int. J.

Cancer 57:920-925).

Although several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini, 1996, Eur. J. Cancer 32A(14):2379-2385), there are disadvantages associated with these proposed inhibitory compounds. For example, suramin is a potent angiogenesis inhibitor, but, at doses required to. . .

. . .

inhibit angiogenesis within the tissue. In one aspect, the tissue is selected from the group consisting of eye tissue, skin tissue, a tumor, a tissue within a joint, bone marrow, nasal epithelium, prostate, ovarian and endometrial tissue. In a preferred embodiment, the tissue is eye. . .

The invention also includes a method of treating a benign neoplasia in a mammal, the method comprising administering PEDF to the mammal, thereby treating the benign-neoplasia. In one aspect, the benign neoplasia is a nasal polyp. In another aspect, the mammal is a human having cystic fibrosis. In yet a further aspect, the benign neoplasia is in the prostate gland.

The invention also includes a method of deterinining the severity of a tumor by assaying for the presence of PEDF within the tumor, wherein the absence of PEDF within the tumor indicates an advanced state and the presence of PEDF within the tumor indicates an early state of the tumor.

. . .

of images of photomicrographs of sections of skin obtained from animals treated with PEDF, wherein hair follicles are depicted. Human SK-N-BE(.2) teuroblastoma tumors growing subcutaneously in nude mice were injected at 2-3 sites/ tumor for four consecutive days with 2 g of purified PEDF. On the fifth day, hair was

noticed
growing over the treated tumors. Histological sections (see
PEDF treated, Figures
8B and 8C) exhibited a three-fold increased density of hair follicles
compared with
6
skin overlying tumors treated with vehicle only (PBS-treated,
Figure 8A). Similar
increases in hair follicle density have been seen in the absence of
tumors following
injection of purified PEDF.

1 5 Figure 1 1, comprising Figures 1 1A-1 1E, is a series of
photoinicrographs taken of human SK-N-BE(2) neuroblastorna
tumors growing in
nude mice that have been injected with the vehicle phosphate buffered
saline (PBS;
Figures I 1A and 1 113) or. . . fixed and stained for neurofilament
protein, an indicator of differentiation. Dramatically increased
staining and
therefore differentiation can be seen in the treated tumors.
In Figure I IC,
differentiation is clearly present along the needle track (clear
rectangle in upper
center) where the PEDF was injected.

. . .
activity of human
vitreous fluid and corneal extracts. Figure 12A: PEDF (O. 1 g/m 1)
purified from
WERI-Rb-27R. (Xu, et al., 1991, Cancer Res. 51:4881) medium
was tested alone or
in combination with antibody against recombinant PEDF (anti-EPC-1; 20
g/mI) or
againstPEDFpeptide(anti-PEDF;l g/ml)foritsabilitytoinhibitthemigrationof
bovine capillary. . .

. . .
and WERI-Rb- 1; all from American Type Culture Collection, Rockville,
Maryland) and from one Rb-positive line (WERI-Rb-27R) (Xu, et al., 1991,
Cancer
Res. 51:4481). Cells were maintained in nonnoxia (N; 21% 02), Hypoxia
(H; 05%
02),orCOCIACO;100 M),andseram-freemediawerecollectedovera48-hour
period from equivalent nurnbers of cells. The blot. . .

. . .
neovascularization associated with several skin
diseases. For example, the inventive method is useful for treating
diseases and
disorders such as psoriasis, scleroden-na, tumors of the skin,
neovascularization as a
consequence of infection (e.g., cat scratch disease, bacterial
ulceration, etc.) or other
skin disorders. Where PEDF. . .

In other embodiments, the tissue is a tumor (e.g., a benign or
cancerous
growth), in which case the inventive method will inhibit the growth of
blood vessels
within and to the tumor, and in some cases, induce
tumor cells to differentiate and thus
divide slowly. Inhibiting the growth of blood vessels within
tumors prevents sufficient
nutrients and oxygen from being supplied to the tumor to
support growth beyond a
given size. Thus, the inventive method can prevent the nucleation of

tumors from
cancerous cells already present due to genetic predisposition (e.g., BRCA-1 mutation carriers, Li Fraumeni patients with p53 mutations, etc.) or the presence of external carcinogens (e.g., tobacco, alcohol, industrial solvents, etc.). Aside from preventing
tumorigenesis, the inventive method can retard the growth of existing tumors, thus rendering them more easily contained and excised and may cause them to regress. This application is highly advantageous for treating tumors that are difficult to operate on (e.g., brain or prostate tumors). In addition, the method is useful for treatment of childhood tumors, including, but not limited to, neuroblastoma. Moreover, minimizing the number of blood vessels within existing tumors lessens the probability that the
tumor will metastasize. In treating tumors, the method can be used alone or in conjunction with other treatments, to control the growth of tumors. Indeed, employing the inventive method can potentiate the response of some tumors to other therapies.

. . .
in conjunction with agents which promote the differentiation of cells, particularly, but not limited to agents which promote the differentiation of brain
tumor cells.

. . .
useful for treatment of nasal polyps, especially in cystic fibrosis patients, leukemia which stems from bone marrow cell abnormal growth, and prostate cancer. The invention can be construed in general to be useful for treatment of benign neoplasias including those in the prostate.

. . .
PEDF may be used to prevent the onset of diabetic retinopathy in a patient having diabetes, to prevent the onset of cancer in persons known to be at risk for certain cancers, and the like. Thus, the methods of the invention should not be construed as being limited to treatment of overt disease,. . .

. . .
tissue specific promoters (e.g., inducible and/or repressible promoters, such as a promoter responsive to TNF or RU486, the metallothionine promoter, etc.), and tumor-specific promoters.

. . .
applied topically to the tissue of interest (e.g., injected, or pumped as a continuous infusion, or as a bolus within a tumor or intercutaneous or subcutaneous site, applied to all or a portion of the surface of the skin, dropped onto the surface of. . .

. . .
invention should also be construed to include the killing of cells by PEDF, particularly cells in existing vessels near or within a
tumor when activated by tumor angiogenesis factors.

Thus, within the context of the
present invention, inhibition of angiogenesis should be construed to include inhibition
of the development. . .

Because it is known that PEDF is reduced or absent from some tumors,
the invention also provides a method of assessing the prognosis of a tumor by assaying
0 for the presence of PEDF within the tumor. The method involves obtaining tissue or
fluid from the tumor and detecting the presence or absence of PEDF within the tissue
or fluid. The tissue or fluid may be, for example, urine, plasma, serum, or vitreous or
aqueous humor. The greater the PEDF concentration within the tumor correlates with
a lesser likelihood that the tumor is undergoing angiogenesis. Thus, a higher PEDF
5 concentration within the tumor is indicative of a relatively early stage of tumorigenesis
and is, therefore, an optimistic indication. Conversely, the absence of PEDF within a
given tumor, or the presence of a low level of PEDF, is indicative of a more advanced
stage of tumerogenesis. Higher or lower. . .

. . .
may be measured in immunological assays, PEDF purification assays or PAGE analysis, etc.). Reagents for detecting the presence of PEDF within such
tumors are known in the art (see, e.g., published international patent applications WO
95/33480 and WO 93/24529).

. . .
inhibits endothelial cell
migration. These results are surprising, given that the PEDF protein is known to
induce neural differentiation of cultured retinoblastoma tumor cells, to be a
neurotrophic factor for cerebellar granular cells and a cytostatic factor for glial cells
(Taniwaki et al., 1997, J.. . .

Table I
Agent ED50-(PM)
PEDF 0 0.5
Thrombospondin 0.5
Endostatin 3.0
Angiostatin 3.5
Retinoic Acid 1 5
Tissue Inhibitor of Metalloproteinase-1 3500
Captopril I Opo
1 0 Ex]!mple 4
These data demonstrate that PEDF inhibits the angiogerlic activity of knov,rn angiogenic agents.

These data also differentiate the region of PEDF that is anti-angiogenic from the region which induces differentiation in retinoblastoma tumor cells and that
which is neurotrophic. It has been shown by (Alberdi et al., 1999, J. Biol. Chem.

. . .
follicles (pilo sebacious gland). An increase in hair follicle density was

1 5 observed in the skin overlying experimentally produced neuroblastoma tumors that
were injected daily for four consecutive days with purified PEDF. This was not
observed in the skin of control animals whose tumors were similarly injected with
saline vehicle.

of 2 [tg of purified histidine-
tagged PEDF in a volume of I 00 [tl of phosphate buffered saline into 2-3 sites/tumor
each day for 4 consecutive days. On the fifth day, a small area of increased hair
growth was noticed over the injection sites. The mice were euthanized using an
overdose of metaphane, and the tumors were surgically removed. Tumor tissue was
sliced and placed in buffered fornialin for at least 24 hours. Tissue was embedded in
paraffin and prepared for histologic examination. The skin overlying neuroblastoma
tumors treated with PEDF had increased hair follicle density when compared with the
skin overlying tumors injected with saline vehicle (Figure 8). Similar increases in hair
follicle density have been seen in the absence of tumors following injection of purified
PEDF.

ExgMple 8

The data presented herein depict the fact that PEDF triggers differentiation of neuroblastoma tumors, thereby providing the basis for treatment of
these tumors. In vitro treatment of neuroblastoma cells, and in vivo treatment of
experimentally produced neuroblastoma tumors with purified histidine tagged-PEDF
protein triggered differentiation of the cells. These data therefore suggest that
administration of PEDF to these cells is an effective means for induce these tumors to
differentiate and therefore grow more slowly.

PEDF is a protein expressed and secreted by many cell types including Schwann cells. Neuroblastomas are malignant tumors, and the presence of Schwann
I 0 cells within these tumors is associated with better outcomes. The data presented herein
indicate that one of the reasons the presence of Schwann cells leads to a favorable
prognosis for neuroblastoma tumors is the fact that these cells produce PEDF. The
PEDF produced therein acts in a paracrine fashion on the tumor cells to induce their
differentiation. Since differentiated neuroblastoma cells grow more slowly, if at all,
1 5 the administration of PEDF to neuroblastoma tumors provides a novel therapy for this
tumor by slowing the growth of the cells. Cell growth is slowed in two ways, (1) by
binding of PEDF to endothelial cells that forin the blood vessels feeding the tumor and
preventing their growth and thereby indirectly inhibiting the tumor, and (2) by binding

of PEDF directly to the tumor cells thereby inducing their differentiation.

In vitro experiments were conducted to verify the effect of PEDF on cell lines derived from neuroblastoma tumors. Two neuroblastoma derived cell lines were obtained from the American Tissue Type and Culture, SK-N-BE(2) and SK-N-SH.

In vivo experiments were conducted to determine the effect of PEDF on neuroblastoma tumors. Human neuroblastomas were experimentally induced in X 106 athymic (nu/nu) mice by injecting I SK-N-BE(2) cells subcutaneously into 2 sites on the hind Ranks of each mouse. When the tumors grew to a palpable size I 0 (approximately 8 mm in diameter) PEDF treatment was started. A total of 2 Ptg of purified histidine-tagged PEDF in a volume of 100]tl of phosphate buffered saline was injected into 2-3 sites/tumor each day for 4 consecutive days. On the fifth day, the mice were euthanized by an overdose of metaphane, and the tumors were surgically removed. Tumor tissue was sliced and placed in buffered formalin for at least 24 1 5 hours. Tissue was embedded in paraffin and. . .

Sections were stained with an antibody that recognized neurofilament'protein (Dako, Carpinteria, CA). Neuroblastoma tumors treated with PEDF exhibited increased differentiation as detennined by acquisition of positive staining for neurofilament protein (Figure 1 1). A total of six SK-N-BE(2) tumors were treated with PEDF and 6/6 were moderately to strongly positive for neurofilament staining. A total of 4 tumors were treated with PBS and all were negative or exhibit focal staining of single cell's with more abundant cytoplasm (Figure I. . .

regulation in most healthy tissues where the influence of naturally occurring inhibitors prevents new vessel growth (Bouck et al., 1996, Adv. Cancer 69:135; Hanahan and Folkirian, 1996, Cell 86:353). The disruption of such controls plays an essential role in the development of a variety of diseases, from arthritis to cancer (Folkman et al., 1995, Molecular Basis of Cancer 206-232). In the healthy inaminalian eye, vessels are normally excluded from the cornea and from the vitreous, both compartments that have been. . .

In studies aimed at identifying antiangiogenic factors in the eye that might be regulated by the retinoblastoma tumor suppressor gene (Rb), media was fractionated where the media was' previously conditioned by a retinoblastoma cell line that had been infected with a retrovirus expressing the wild-type Rb gene, WERI-Rb-27R. (Xu et al., 1991, Cancer Res. 51:448 1). A protein

punification scheme resulted in
a 1000- to 1250-fold enrichment of antiangiogenic activity and a single
50-kD. . . (Pharmacia) with 0.5 M a-methyl-D-mannopyranoside,
and elution from a HiTrap heparin Sepharose column (Phan-nacia) with
increasing
NACI gradient. (Xu, et al., 1991, Cancer Res. 51:4481).
Purification was monitored
by an endothelial cell migration assay, and the yield was 17.5%.
Migration assays
were performed in quadruplicate. . .

To further investigate the effect of oxygen regulation on PEDF,
retinoblastoma tumor cells were maintained in low oxygen
(0.5%) or in chemical
agents that simulate hypoxia (Goldberg, et al., 1988, Science 242:1214).
As. . .

Medium conditioned by hypoxic tumor cells was more angiogenic
than
that conditioned by normoxic tumor cells (Figure 15C). Hypoxia
reduced the
concentration of medium needed to induce 50% of maximal endothelial cell
chemotaxis from 4.0 to 0.3. . . angiogenic activity of these cells,
did not
reduce the angiogenic activity of the hypoxic conditioned media, but
neutralization of
PEDF made normoxic tumor media as angiogenic as that derived
from hypoxic cells.

(Figure 15C). Consistent with these in vitro studies, tumor
cells present in 12 out of 12
human retinoblastoma pathologic specimens failed to stain for PEDF,
presumably in
part because of limited oxygen in the tumor environment
(Gulledge and Dewhirst,
1996, Anticancer Res. 16:741), whereas adjacent normal retina was
positive.
. . .
of blood
vessel growth in the eye by creating a permissive environment for
angiogenesis When
oxygen is limiting (as it is in tumors and in retinopathics)
and an inhibitory
environment when oxygen concentrations are normal or high. Given its
high potency
and the broad range. . .

CLMEN. . . 5 The method of claim 4, wherein said tissue is selected from the
group consisting of eye tissue, skin tissue, a tumor, a tissue
within a joint, bone
marrow, nasal epithelium, prostate, ovarian and endometrial tissue.
. . .
for said PEDF to inhibit angiogenesis
in said eye, thereby treating said macular degeneration.
I 1. A method of treating a benign neoplasia in a mammal, said
method
comprising administering PEDF to said mammal, thereby treating said
benign
neoplasia.

12 The method of claim 1 1, wherein said benign neoplasia is a
nasal
polyp.

14 The method of claim I 1, wherein said benign neoplasia is in the
prostate gland.

. . .

fragment
of PEDF comprises amino acids 44-77 of SEQ ID NO: 1.
3 8. A method of determining the severity of a tumor by assaying for the
presence of PEDF within the tumor, wherein the absence of PEDF within the tumor
indicates an advanced state and the presence of PEDF within the tumor indicates an
early state of the tumor.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007)

     FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007
               E "CAPTOPRIL"/CN 25
L1             1 S E3
               E "LOSARTAN"/CN 25
L2             1 S E3

     FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007
L3          2324 S L1/THU
L4          1975 S L2/THU
L5        788148 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L6            26 S L3 (L) L5
L7             8 S L6 NOT PY>2000
L8             4 S L7 AND HUMAN
L9            10 S L4 (L) L5

     FILE 'PCTFULL' ENTERED AT 12:54:54 ON 12 APR 2007
L10         3752 S CAPTOPRIL
L11         1805 S LOSARTAN
L12         4267 S L10 OR L11
L13       110137 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L14         2500 S L13 AND L12
L15          311 S L14 NOT PY>1999

=> s l15 and human
         228055 HUMAN
          89732 HUMANS
         238084 HUMAN
                (HUMAN OR HUMANS)
L16         280 L15 AND HUMAN

=> s l10/ab
L17          24 (CAPTOPRIL/AB)

=> s l11/ab
             39 LOSARTAN/AB
              1 LOSARTANS/AB
L18          39 (LOSARTAN/AB)
                ((LOSARTAN OR LOSARTANS)/AB)

=> s l10/clm
L19         633 (CAPTOPRIL/CLM)

=> s l11/clm
L20         362 (LOSARTAN/CLM)
```

```
=> s l5/clm
         25411 CANCER?/CLM
          4141 NEOPLAS?/CLM
         16849 TUMOR?/CLM
          4957 CARCINOM?/CLM
L21      36455 (CANCER?/CLM OR NEOPLAS?/CLM OR TUMOR?/CLM OR CARCINOM?/CLM)

=> s l17 or l18 or l19 or l20
L22        801 L17 OR L18 OR L19 OR L20

=> s l22 and l21
L23        217 L22 AND L21

=> s l23 not py>1999
        807628 PY>1999
L24         16 L23 NOT PY>1999

=> d ibib 1-5

L24    ANSWER 1 OF 16    PCTFULL   COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER:        1999043663 PCTFULL  ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH):         N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA
                         DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR
                         THE TREATMENT OF ISCHEMIA
TITLE (FRENCH):          DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE
                         SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE
                         TRAITEMENT DE L'ISCHEMIE
INVENTOR(S):             HAMANAKA, Ernest, S.;
                         GUZMAN-PEREZ, Angel;
                         RUGGERI, Roger, B.;
                         WESTER, Ronald, T.;
                         MULARSKI, Christian, J.
PATENT ASSIGNEE(S):      PFIZER PRODUCTS INC.;
                         HAMANAKA, Ernest, S.;
                         GUZMAN-PEREZ, Angel;
                         RUGGERI, Roger, B.;
                         WESTER, Ronald, T.;
                         MULARSKI, Christian, J.
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 9943663           A1 19990902
DESIGNATED STATES
       W:                AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
                         ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
                         KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
                         RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
                         ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
                         TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
                         SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
PRIORITY INFO.:          US 1998-60/076,362      19980227
APPLICATION INFO.:       WO 1999-IB206        A  19990205

L24    ANSWER 2 OF 16    PCTFULL   COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER:        1999030690 PCTFULL  ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH):         ORAL DELIVERY FORMULATION
TITLE (FRENCH):          FORMULATION D'ADMINISTRATION PAR VOIE ORALE
INVENTOR(S):             COMPTON, Bruce, Jon;
                         SOLARI, Nancy, E.;
                         FLANAGAN, Margaret, A.
PATENT ASSIGNEE(S):      AXIA THERAPEUTICS, INC.;
                         COMPTON, Bruce, Jon;
```

SOLARI, Nancy, E.;
FLANAGAN, Margaret, A.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9930690	A1	19990624

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 1997-60/069,501 19971215
US 1998-60/073,867 19980204
US 1998-09/055,163 19980404
US 1998-09/055,560 19980406
APPLICATION INFO.: WO 1998-US26627 A 19981215

L24 ANSWER 3 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1999018956 PCTFULL ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH): 12(S)-HETE RECEPTOR BLOCKERS
TITLE (FRENCH): INHIBITEURS DU RECEPTEUR DE 12(S)-HETE
INVENTOR(S): NATARAJAN, Rama, Devi;
NADLER, Jerry, L.
PATENT ASSIGNEE(S): CITY OF HOPE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9918956	A1	19990422

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 1997-60/062,335 19971015
APPLICATION INFO.: WO 1998-US21570 A 19981014

L24 ANSWER 4 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1999008596 PCTFULL ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH): MEASUREMENT OF CAPILLARY RELATED INTERSTITIAL FLUID USING ULTRASOUND METHODS AND DEVICES
TITLE (FRENCH): MESURE DU FLUIDE INTERSTITIEL PROPRE AUX CAPILLAIRES UTILISANT DES METHODES ET DES DISPOSITIFS ECHOGRAPHIQUES
INVENTOR(S): LANG, Philipp;
MENDLEIN, John, D.
PATENT ASSIGNEE(S): LANG, Philipp;
MENDLEIN, John, D.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9908596	A1	19990225

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 1997-08/914,527 19970819
APPLICATION INFO.: WO 1998-US17238 A 19980819

L24 ANSWER 5 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998051282 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
TITLE (FRENCH): MATRICES POREUSES SOLIDES, LEUR PROCEDE DE FABRICATION ET LEUR UTILISATION
INVENTOR(S): UNGER, Evan, C.
PATENT ASSIGNEE(S): IMARX PHARMACEUTICAL CORP.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9851282	A1	19981119

DESIGNATED STATES
W: AU BR CA CN JP KR NZ AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE
PRIORITY INFO.: US 1997-60/046,379 19970513
US 1998-9/075,477 19980511
APPLICATION INFO.: WO 1998-US9570 A 19980512

=> d ibib 6-10

L24 ANSWER 6 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998036784 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): COATED IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE DOTE D'UN REVETEMENT
INVENTOR(S): RAGHEB, Anthony, O.;
BATES, Brian, L.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
VOORHEES, William, D., III;
GERSHLICK, Anthony, H.
PATENT ASSIGNEE(S): COOK INCORPORATED
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9836784	A1	19980827

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: US 1997-60/038,459 19970220
APPLICATION INFO.: WO 1998-US3438 A 19980220

L24 ANSWER 7 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998032718 PCTFULL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): NEW FATTY ACID DERIVATIVES
TITLE (FRENCH): NOUVEAUX DERIVES D'ACIDE GRAS
INVENTOR(S): MYHREN, Finn;
BORRETZEN, Bernt;
DALEN, Are;
SANDVOLD, Marit, Liland
PATENT ASSIGNEE(S): NORSK HYDRO ASA;
MYHREN, Finn;
BORRETZEN, Bernt;
DALEN, Are;
SANDVOLD, Marit, Liland
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9832718	A1	19980730

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: GB 1997-9701441.9 19970124
APPLICATION INFO.: WO 1998-NO21 A 19980123

L24 ANSWER 8 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998032022 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): GROWTH FACTOR-DEPENDENT DISEASES
TITLE (FRENCH): MALADIES LIEES AU FACTEUR DE CROISSANCE
INVENTOR(S): EPSTEIN, Richard, John
PATENT ASSIGNEE(S): IMPERIAL EXPLOITATION LIMITED;
EPSTEIN, Richard, John
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9832022	A1	19980723

DESIGNATED STATES
W: JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
PRIORITY INFO.: GB 1997-9700933.6 19970117
APPLICATION INFO.: WO 1998-GB33 A 19980115

L24 ANSWER 9 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998018610 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES
TITLE (FRENCH): INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION CONTROLEE
INVENTOR(S): VAN LENGERICH, Bernhard, H.
PATENT ASSIGNEE(S): VAN LENGERICH, Bernhard, H.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9818610	A1	19980507

DESIGNATED STATES
W: AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

PRIORITY INFO.: US 1996-60/029,038 19961028
US 1997-60/052,717 19970716
APPLICATION INFO.: WO 1997-US18984 A 19971027

L24 ANSWER 10 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998017331 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): SILVER IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE ET CONTENANT DE L'ARGENT
INVENTOR(S): BATES, Brian, L.;
OSBORNE, Thomas, A.;
ROBERTS, Joseph, W.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
RAGHEB, Anthony, O.;
VOORHEES, William, D., III
PATENT ASSIGNEE(S): COOK INCORPORATED;
MED INSTITUTE, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817331	A1	19980430

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW SD
SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES
FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG
PRIORITY INFO.: US 1996-60/029,158 19961024
US 1996-8/741,565 19961031
US 1997-8/803,843 19970224
APPLICATION INFO.: WO 1997-US19188 A 19971023

=> d ibib 11-16

L24 ANSWER 11 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998015574 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN
TITLE (FRENCH): PROCEDES ET COMPOSITIONS DESTINES A PRODUIRE DE L'ANGIOSTATINE
INVENTOR(S): SOFF, Gerald;
GATELY, Stephen, T.;
TWARDOWSKI, Przemyslaw
PATENT ASSIGNEE(S): NORTHWESTERN UNIVERSITY;
SOFF, Gerald;
GATELY, Stephen, T.;
TWARDOWSKI, Przemyslaw
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9815574	A1	19980416

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS
MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: US 1996-8/710,305 19960917
APPLICATION INFO.: WO 1997-US16539 A 19970917

L24 ANSWER 12 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1997031654 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM DRUGS
TITLE (FRENCH): DONNEURS D'OXYDE NITRIQUE CAPABLES DE DIMINUER LA TOXICITE DE MEDICAMENTS
INVENTOR(S): DEL SOLDATO, Piero
PATENT ASSIGNEE(S): NICOX S.A.;
DEL SOLDATO, Piero
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9731654	A1	19970904

DESIGNATED STATES
W: AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: IT 1996-MI96A000352 19960226
APPLICATION INFO.: WO 1997-EP873 A 19970224

L24 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1995018603 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER
TITLE (FRENCH): DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE CONTENANT DE LA POLYVINYLPYRROLIDONE EN TANT QU'AMPLIFICATEUR DE SOLUBILITE
INVENTOR(S): MIRANDA, Jesus;
SABLOTSKY, Steven
PATENT ASSIGNEE(S): NOVEN PHARMACEUTICALS, INC.;
MIRANDA, Jesus;
SABLOTSKY, Steven
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9518603	A1	19950713

DESIGNATED STATES
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: US 1994-8/178,558 19940107
APPLICATION INFO.: WO 1995-US22 A 19950109

L24 ANSWER 14 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1993024154 PCTFULL ED 20020513 <<LOGINID::20070412>>
TITLE (ENGLISH): BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM
TITLE (FRENCH): SYSTEME DE LIBERATION CONTROLEE BIODEGRADABLE FILE EN FUSION
INVENTOR(S): FUISZ, Richard, C.
PATENT ASSIGNEE(S): FUISZ TECHNOLOGIES, LTD.;
FUISZ, Richard, C.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9324154	A1	19931209

DESIGNATED STATES
W: AU CA HU JP KR PL US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
PRIORITY INFO.: US 1992-7/893,238 19920603
APPLICATION INFO.: WO 1993-US5307 A 19930602

L24 ANSWER 15 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1991016882 PCTFULL ED 20020513 <<LOGINID::20070412>>
TITLE (ENGLISH): DIRECT SPRAY-DRIED DRUG/LIPID POWDER COMPOSITION
TITLE (FRENCH): COMPOSITION DE MEDICAMENT/LIPIDES EN POUDRE SECHEE PAR PULVERISATION DIRECTE
INVENTOR(S): DURRANI, Manzer;
FITCH, Wendy;
FOK, Katherine;
RADHAKRISHNAN, Ramachandran;
USTER, Paul, S.
PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9116882	A1	19911114

DESIGNATED STATES
W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
PRIORITY INFO.: US 1990-520,792 19900508
APPLICATION INFO.: WO 1991-US3092 A 19910506

L24 ANSWER 16 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1990006775 PCTFULL ED 20020513 <<LOGINID::20070412>>
TITLE (ENGLISH): A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS
TITLE (FRENCH): NOUVELLE COMPOSITION DE LIPOSOMES NON PHOSPHOLIPIDIQUE A LIBERATION SOUTENUE DE MEDICAMENTS
INVENTOR(S): RADHAKRISHNAN, Ramachandran
PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9006775	A1	19900628

DESIGNATED STATES
W: AT AU BE CH DE DK ES FI FR GB IT JP LU NL NO SE
PRIORITY INFO.: US 1988-284,158 19881214
US 1988-284,216 19881214
US 1989-Not furnished 19891201
APPLICATION INFO.: WO 1989-US5525 A 19891206

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.29	74.15

STN INTERNATIONAL LOGOFF AT 12:59:14 ON 12 APR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded
NEWS 28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 29	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 30	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),